Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses.

Revenues for the quarter came in at $24.2 million as against $25.7 million in the year-ago quarter, down 5.8%. Research and development costs increased 5% to $23.2 million primarily because of increased costs for clinical and pre-clinical programs coupled with increased R&D headcount to support Alnylam’s alliances and development programs.    General and administrative expenses increased 56% to $10.7 million. The increase in general and administrative spend was primarily driven by higher professional service fees in association with business activities, primarily legal activities, coupled with increased stock based compensation expenses.   Alnylam exited the quarter with $453.5 million in cash, cash equivalents and marketable securities

...

For Immediate Release

Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Enzon (ENZN), Merck (MRK), OSI Pharmaceuticals (OSIP), Pfizer (PFE) and Bank of America Corporation (BAC).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

Enzon Beats, Announces Sell-off

Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday November 10, 2009

DrStockPick.com Stock Report!

PWRM, TEVA

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Enzon (ENZN) achieved break-even earnings during the third quarter of 2009, better than the Zacks Consensus Estimate of loss of 7 cents but below the year-ago earnings of 1 cent. The company reported revenues of $44.6 million, a decline of 9% compared to $48.8 million reported in the third quarter of 2008. Enzon records revenues from three sources -- products, royalties and contract manufacturing. The three segments recorded a decline of 1%, 6% and 56%, respectively, compared to the year-ago period. Enzon has four marketed products -- Oncaspar for the treatment of acute lymphoblastic leukemia (ALL); DepoCyt for lymphomatous meningitis; Abelcet for antifungal infection related to cancer and Adagen used to treat severe combined immunodeficiency disease (SCID), commonly known as the "bubble boy" disease. Apart from Oncaspar, whose sales remained unchanged from the year-ago period, the other three recorded a decline of 4%, 15% and 10%, ...

HealthSport Inc. is the preeminent formulator and developer of edible, multi-layer film strips that deliver over-the-counter drug, nutritional and dietary supplement actives through buccal (between the cheek and gum) and sublingual absorption as well as oral ingestion. The company’s proprietary edible film strip technology has five patents pending and is believed to be superior to competitors’ film strips already on the market.

The company announced today that its strategic manufacturing partner, SMI Manufacturing, has agreed to invest $10 million into HealthSport. The investment is expected to accelerate the company’s growth and strengthen its alliances with large pharmaceutical companies to provide this breakthrough, next-generation drug delivery technology.

HealthSport will use the funds in a multitude of ways – as working capital, to provide funds for research & development, and to enhance the company’s current manufacturing plant. In exchange for the $10 million, SMI will receive a 55% stake in HealthSport.

HealthSport’s drug delivery

...

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition, including Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their blockbuster products or likely to face them going forward, the companies have been looking toward mergers ...

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 11/09/09 — Global Health Ventures Inc. (OTCBB: GHLV), or the “Company” a Specialty Pharma is pleased to announce today that it has completed the prototype manufacturing of the drug “X-Excite” Global’s male enhancement drug. The manufacturing of the product was carried out under contract with Vida Pharma of Montreal, Canada. Vida Pharma specialized in the designing of the new tablet size, taste, and hardness. The Company has manufactured over 4000 pills from several different incipient and coatings that are all safe for human consumption. These various batches will be tested at the University of British Columbia, Canada for independent evaluation in regards to drugs adsorption, taste, color and hardness. If the samples meet our end goals then the drug will be ready for mass production under the proprietary formula for testing in humans and finally applying for regulatory approval.

The Company plans to

...

For Immediate Release

Chicago, IL – November 9, 2009 – Zacks Equity Research highlights Inspire Pharmaceuticals, Inc. (ISPH) as the Bull of the Day and Sears Holdings (SHLD) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Moody's Corp.(MCO), CBS Corporation (CBS) and Forest Oil Corporation (FST).

Full analysis of all these stocks is available at http://at.zacks.com/?id=5506

Here is a synopsis of all five stocks:

Bull of the Day:

Inspire Pharmaceuticals, Inc. (ISPH) is a specialty pharmaceutical company focused on the development and commercialization of treatments for respiratory and ophthalmologic disorders.

Currently, the company has three products on the market and a robust pipeline. We see strong top line growth from 2009 and beyond. Inspire just reported positive phase III data of Denufosol for CF. The company has a strong collaborative alliance with Allergan Pharmaceuticals for key products

...

China Medicine Corp. is a developer and leading distributor of prescription and over-the-counter drugs, traditional Chinese medicine products, nutritional and dietary supplements, and medical devices and formulations in China.

The company announced today that through its wholly-owned subsidiary in China, Konzern Pharmaceuticals, it has signed an equity transfer agreement to acquire 100% of equity interests in Sinoform Limited, a British Virgin Islands corporation which is the sole shareholder of Guangzhou LifeTech Pharmaceuticals. LifeTech Pharmaceuticals is a developer, manufacturer and marketer of pharmaceutical products and traditional Chinese medicines in China.

The acquisition is expected to close before the end of the year and China Medicine will acquire Guangzhou LifeTech for 57 million renminbi or about $8.3 million cash and the assumption of about $13.2 million in debt. Upon closing of the acquisition, the company will receive all of LifeTech’s assets, including a portfolio of 39 Western and traditional Chinese medicine products. LifeTech’s top-selling

...

Depomed, Inc (NASDAQ:DEPO) today reported financial results for the third quarter that ended on September 30, 2009. The revenue for the three months ended September 30, 2009 was US$23 million compared to US$14.1 million for the three months ended September 30, 2008. The revenue in the last three months ended this September also includes license payments from Merck &Co. Inc. as Depomed has entered a license agreement with Merck for fixed dose combinations of sitagliptin and extended release metformin which they finalized in July 2009.

Executives of Depomed announced that they have achieved significant milestones in the third and early fourth quarter and have also completed a transaction with Merck that has provided them a reason to rejoice and have a stronger and profitable balance sheet this quarter. Depomed is a specialty pharmaceutical company which has many product candidates in the pipeline with few of products already in Phase 3

...